Therapeutic Options to Prevent Severe COVID-19 in Immunocompromised People (Webinar)

Mary Madison, RN, RAC-CT, CDP 
Clinical Consultant – Briggs Healthcare

The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for monoclonal antibodies to treat COVID-19 for certain patients. Monoclonal antibodies may be available through expanded access programs to treat COVID-19 for immunocompromised patients. However, the efficacy of use for immunocompromised patients is unclear.

During this COCA Call, presenters will discuss the FDA’s role in issuing EUAs for certain monoclonal antibodies, options for compassionate use, the process for ordering and distributing monoclonal antibodies, and current data on using monoclonal antibodies for both non-hospitalized and immunocompromised patients. Presenters will also cover preventing, diagnosing, and treating COVID-19 in immunocompromised patients, including the role of monoclonal antibodies, serologic testing, and potential third dose of COVID-19 vaccinations.

Date: Thursday, August 12, 2021

Time: 2:00 PM – 3:00 PM ET

A few minutes before the webinar starts, please click on the Zoom link below to join:

Passcode: 980771

Or Telephone:

US: +1 669 254 5252

or +1 646 828 7666

or +1 669 216 1590

or +1 551 285 1373 

Or One-tap mobile: 
US: +16692545252,,1612254638#,,,,*980771# 

or +16468287666,,1607826639#,,,,*183098# 

Webinar ID: 161 225 4638

International numbers available:

If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.

The slide set will be available on the day of the call under “Call Materials” on the COCA Call webpage

Free Continuing Education (CE) will be offered for this COCA Call.

Registration is not required.